Debut Dialogues – Our First CPHI: In Conversation with Ninestars’ Leaders

Published: 27 Oct 2025

As the life sciences community prepares to gather in Frankfurt for CPHI 2025, from October 28 to 30, Ninestars is excited to participate in the event for the first time. We are looking forward to engage with customers, partners, peers, and innovators who are shaping the future of the industry.

This participation comes at a time when packaging is moving from being a backroom process to a strategic driver of quality, compliance, and speed. The growing role of AI and automation is redefining how pharmaceutical and medical device companies manage creative and proofing workflows, ensuring precision while reducing time to market.

At the centre of this shift is AOTM PACKX, our intelligent automation platform for packaging artwork. It brings together creative teams, regulatory reviewers, and production stakeholders in one connected ecosystem—helping companies simplify complexity and build packaging operations that are faster, more transparent, and fully compliant.

Ahead of CPHI 2025, we sat down for Five Questions with Mohan Doshi, Chief Business Officer, to discuss what is driving the change in life sciences packaging, how AOTM PACKX supports this transformation, and why this year’s CPHI holds special significance for Ninestars.

What strategic vision led to the creation of PACKX?

AOTM PACKX was born out of our broader strategic vision to extend Ninestars’ automation capabilities into new markets and verticals where creative, data, and content workflows intersect. Over the past four years, our sustained R&D investments have matured into tangible outcomes—both internally through operational excellence, and externally through client success.

Recognizing the growing need for intelligent automation in regulated and highly creative environments, we saw an opportunity to redefine how business outcomes are measured in terms of speed, compliance, and quality. AOTM PACKX is the result—a focused innovation designed to disrupt the packaging and labelling automation landscape through measurable business impact.

How are life sciences clients responding to automation in regulated creative workflows?

Life sciences organizations are under intense pressure to accelerate global product launches amidst shorter patent lifecycles and evolving regulatory demands. Automation is no longer optional—it’s mission-critical.

Clients see AOTM PACKX as a trusted enabler to achieve faster time-to-market without compromising on compliance, audit readiness, or design integrity. The response has been exceptional, largely because our approach blends deep domain expertise with regulatory sensitivity. We help clients transition from manual, fragmented creative workflows to intelligent, compliant, and scalable automation ecosystems.

How do you see PACKX evolving as part of Ninestars’ larger automation ecosystem?

Ninestars’ automation vision revolves around three pillars—Content, Data, and Creative. While the AOTM platform provides a horizontal automation foundation across industries, AOTM PACKX is a verticalized extension built specifically for packaging and labelling automation in regulated sectors like life sciences.

As we expand AOTM PACKX to cover more use cases—from artwork proofing to multilingual compliance automation—we see it becoming a cornerstone in Ninestars’ larger intelligent automation ecosystem. The convergence of content intelligence, regulatory data, and creative automation will unlock significant value for pharma and healthcare clients in the years ahead.

What does success look like for Ninestars in this space over the next few years?

Success for us is defined by business impact at scale—transforming how life sciences organizations manage packaging and labelling workflows globally.

In the next few years, we envision AOTM PACKX driving measurable outcomes across three dimensions:

Speed: Reducing packaging and labelling cycle times by 40–60%.
Compliance: Achieving near-zero audit findings through automation-driven traceability.
Scalability: Enabling global rollouts across markets and regulatory regimes through a unified automation framework.

Ultimately, success means becoming the preferred automation partner for life sciences brands seeking to balance agility, compliance, and creative excellence.

What are you most looking forward to at CPHI, and how does it align with Ninestars’ broader automation vision?

CPHI provides the perfect platform to engage with global pharma leaders who are reimagining the future of regulated operations through automation. We look forward to exchanging insights on how creative and content automation can directly influence market readiness, regulatory agility, and brand consistency.

For Ninestars, this aligns perfectly with our broader vision—to make intelligent automation a business enabler rather than just a technology initiative. AOTM PACKX embodies that vision by demonstrating how automation can drive measurable outcomes—from faster approvals to compliant global launches—impacting not just processes, but the entire value chain.

Let’s Connect: Visit Ninestars’ booth at CPHI Frankfurt 2025

If you are attending CPHI 2025 in Frankfurt, we would be happy to connect in person. Visit us at Hall 4.0, Booth 4P12 to learn more about AOTM PACKX and how AI and automation are shaping the future of life sciences packaging. For additional information, you can visit https://www.ninestarsglobal.com/CPHI-2025/ or reach us at contactus@ninestars.in.

Stay tuned for more conversations from Ninestars’ leaders as part of the Debut Dialogues series.

Post Your Comments Cancel reply

Get the most out of your business by innovating
with Ninestars.

Debut Dialogues – Our First CPHI: In Conversation with Ninestars’ Leaders

Trending Articles

Debut Dialogues – Our First CPHI: In Conversation with Ninestars’ Leaders

Debut Dialogues – Our First CPHI: In Conversation with Ninestars’ Leaders

Post Your Comments Cancel reply